Fate Therapeutics

United States
San Diego, California, United States, 92037

Company profile

Fate Therapeutics company profile

Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

Business identity

Contact email
[email protected]
Phone number
8588751802
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2007-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
18
Total equity funding
$1.3B
Last funding
Grant / $7.9M / 2025-01-30
Last equity funding
Post IPO Equity / $100M
Investors
13
Lead investors
3
Founders
8
Articles
214
Exited on
2013-10-01

Founders and investors

Founders

Alex RivesDavid ScaddenLeonard ZonMichael RudnickiPhillip BeachyRandall MoonRudolf JaenischSheng Ding

Lead investors

California Institute for Regenerative MedicineOVP Venture PartnersSilicon Valley Bank

Investors

Adage Capital ManagementARCH Venture PartnersOrbiMedPolaris PartnersVenrock